Pharmacogenomic studies in Mexico, central America and Cuba in amerindians groups: Clinical applications and toxicology

In Latin America, the first study focused on the pharmacogenetics of CYP2D6 was developed in 1986 by the team headed by Arias TD et al., with Cuna Amerindians from Panama. Since that date up to 2015 there have been published 29 studies about CYP2D6 in Latin American countries; from which 17 were developed in Mexico, 3 in Cuba, and 9 in Central America (2 from Nicaragua, 2 from Costa Rica and 5 from Panama). Moreover, 23 studies were undertaken in Amerindian and Mestizo populations and finally, 6 with clinical application. Therefore, it is important to accurately spread the hard work of research being carried out in this part of the globe with crucial implications for improvement of regional personalized therapy.